The Globe and Mail reports in its Tuesday, Sept. 22, edition that Congolese authorities are starting to distribute a Canadian-developed vaccine to protect 20,000 health workers from a spreading Ebola outbreak. The Globe's Geoffrey York writes that experts, however, believe Ottawa could do more to develop effective vaccines for the current virus species. The vaccine, known as Ervebo and manufactured by Merck, was developed at the National Microbiology Laboratory in Winnipeg and has been deployed in outbreaks of the most common Ebola species, known as the Zaire virus. Its protective value against the Bundibugyo Ebola virus -- the cause of the latest outbreak -- is unknown, but health authorities have decided to try it anyway in a large-scale study. Ervebo was developed and licenced solely for the Zaire virus, but it is the only Ebola vaccine available in large quantities today. There are no proven vaccines for Bundibugyo. A leading Canadian vaccine researcher suggested in 2014 that the basic platform of what became Ervebo could be developed to target the Bundibugyo Ebola virus, documents show. The work was never done, and the international focus today has shifted to potential vaccines from other developers.